Postoperative Ocular Pain — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for postoperative ocular pain. 41 active patents protecting 3 drugs from 3+ originators. First major cliff: 2027. Daily refresh.

3
Approved drugs
41
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Postoperative Ocular Pain

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 24 patents Hisamitsu Pharmaceutical Co., Inc 14 patents Harrow Health 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating postoperative ocular pain. Each bar = one year. Y-axis scaled to peak year (17 patents).

13
27
1
28
9
29
17
30
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Arthrotec
Diclofenac Sodium
 Pfizer 24 73 — 2027-03-22
Voltaren
DICLOFENAC
 Hisamitsu Pharmaceutical Co., Inc 14 57 — 2030-04-23
Nevanac
NEPAFENAC
 Harrow Health 3 60 — 2027-01-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7834059 Nevanac method of use 85 2027-01-31
8946292 Arthrotec method of use 80 2027-03-22
8871809 Arthrotec method of use 80 2027-10-17
8563613 Arthrotec method of use 80 2027-10-17
8252838 Arthrotec method of use 80 2028-04-21
9539335 Arthrotec method of use 75 2027-10-17
9132110 Arthrotec method of use 75 2027-10-17
9220784 Arthrotec method of use 75 2027-10-17
9168305 Arthrotec method of use 75 2027-10-17
9339551 Arthrotec method of use 75 2027-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8921337 Nevanac formulation 48 2032-03-31
9662398 Nevanac formulation 48 2030-12-01
9180096 Voltaren formulation 48 2030-04-23
9017721 Voltaren formulation 48 2030-04-23
9173854 Voltaren formulation 48 2030-04-23
9017721 Voltaren formulation 48 2030-04-23
9173854 Voltaren formulation 48 2030-04-23
9180096 Voltaren formulation 48 2030-04-23
8679544 Voltaren formulation 53 2030-04-23
8679544 Voltaren formulation 53 2030-04-23

Related